The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

Abstract Background Long-acting injectable antipsychotics (LAIs) are an essential maintenance treatment option for individuals with schizophrenia or bipolar I disorder (BP-I). This report summarizes a roundtable discussion on the impact of COVID-19 on the mental healthcare landscape and use of LAIs...

Full description

Bibliographic Details
Main Authors: Christoph U. Correll, Craig Chepke, Paul Gionfriddo, Joe Parks, Phyllis Foxworth, Anirban Basu, Teri S. Brister, Dawn Brown, Christopher Clarke, Youssef Hassoun
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Psychiatry
Subjects:
Bipolar I disorder
Collaborative-care
COVID-19
Long-acting injectable antipsychotics
Schizophrenia
Online Access:https://doi.org/10.1186/s12888-022-03685-w

Internet

https://doi.org/10.1186/s12888-022-03685-w

Similar Items